Want to see LITS full AI Analyst Report?
Top Page
Lite Strategy
(NASDAQ:LITS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▲(50.00% Upside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak financial performance (recent zero revenue, recurring losses, and persistent negative cash flow), partially offset by constructive technical momentum (price above key moving averages with positive MACD). Valuation is also pressured by a negative P/E, while the recent corporate strategy/buyback authorization provides a modest supportive signal but does not offset the underlying financial volatility.
Positive Factors
Conservative leverage
Zero total debt across 2024–2026 gives Lite Strategy a conservative leverage profile and avoids interest obligations. This flexibility can help preserve capital for treasury, pharmaceutical, or ecosystem initiatives, although it does not by itself establish operating profitability.
Negative Factors
No current revenue
Revenue falling to zero for two consecutive annual periods indicates that the company currently lacks a dependable operating revenue base. Without recurring sales, strategic initiatives remain difficult to evaluate through business performance, and future earnings depend on restoring commercial activity.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Zero total debt across 2024–2026 gives Lite Strategy a conservative leverage profile and avoids interest obligations. This flexibility can help preserve capital for treasury, pharmaceutical, or ecosystem initiatives, although it does not by itself establish operating profitability.
Read all positive factors
Lite Strategy (LITS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$41.81M
Dividend Yield38.63%
Average Volume (3M)697.01K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth16.97%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-9.11
Shares Outstanding30,407,269
10 Day Avg. Volume1,429,552
30 Day Avg. Volume697,007
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-3.49
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$25.00M
Lite Strategy Business Overview & Revenue Model
Company Description
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially...
Lite Strategy Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
47
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 65.30M | 48.82M | 40.70M |
| Gross Profit | 0.00 | -368.00K | 65.30M | 48.82M | 40.70M |
| EBITDA | -12.27M | -17.09M | 25.82M | -36.38M | -75.16M |
| Net Income | -71.15M | -15.95M | 17.78M | -31.84M | -54.45M |
Balance Sheet | |||||
| Total Assets | 42.69M | 18.29M | 41.38M | 120.81M | 177.84M |
| Cash, Cash Equivalents and Short-Term Investments | 5.71M | 18.01M | 38.34M | 100.69M | 153.25M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.73M | 9.64M |
| Total Liabilities | 1.07M | 1.35M | 8.36M | 96.19M | 125.43M |
| Stockholders Equity | 41.62M | 16.93M | 33.02M | 24.62M | 52.41M |
Cash Flow | |||||
| Free Cash Flow | -9.12M | -20.84M | -50.48M | -52.52M | -49.23M |
| Operating Cash Flow | -9.12M | -20.84M | -50.47M | -52.48M | -48.75M |
| Investing Cash Flow | -95.11M | 35.15M | 49.14M | 53.69M | 6.89M |
| Financing Cash Flow | 91.92M | 0.00 | -11.87M | -40.00K | 49.05M |
Lite Strategy Technical Analysis
Positive
1.00
Price Trends
1.05
Positive
1.01
Positive
1.12
Positive
Market Momentum
0.10
Negative
59.73
Neutral
64.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Positive. The current price of 1 is below the 20-day moving average (MA) of 1.18, below the 50-day MA of 1.05, and below the 200-day MA of 1.12, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 59.73 is Neutral, neither overbought nor oversold. The STOCH value of 64.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LITS.
Lite Strategy Risk Analysis
Lite Strategy disclosed 29 risk factors in its most recent earnings report. Lite Strategy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lite Strategy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $41.81M | -0.14 | -97.27% | 38.63% | ― | 16.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $73.32M | -3.46 | -161.58% | ― | ― | 23.02% | |
48 Neutral | $20.81M | -0.36 | -618.87% | ― | ― | 73.74% | |
47 Neutral | $316.02M | -4.95 | -75.35% | ― | 220.34% | 55.73% | |
42 Neutral | $32.40M | -3.59 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
LITS
Lite Strategy
1.32
-1.36
-50.75%
ABVC
ABVC BioPharma
1.06
-1.96
-64.90%
JSPR
Jasper Therapeutics
0.58
-1.84
-76.03%
PRLD
Prelude Therapeutics
3.91
2.47
171.53%
GANX
Gain Therapeutics
1.73
-0.13
-6.99%
ESLA
Estrella Immunopharma
0.47
-0.85
-64.70%
Lite Strategy Corporate Events
Business Operations and StrategyStock Buyback
Lite Strategy Unveils Litecoin-Focused Investor Strategy Update
Positive
Jul 24, 2026
Lite Strategy has released new investor presentation materials outlining its strategy as an actively managed Litecoin-focused public vehicle and detailing its mission to institutionalize Litecoin as a strategic treasury asset. The materials highli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.